
Loading, please wait...

Loading, please wait...







This study evaluates the prognostic significance of the modified Glasgow Prognostic Score (mGPS) and systemic immune-inflammation index (SII) in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel, identifying them as key predictors for survival.



